Amit Gupta Sells 5,964 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 5,964 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $21,887.88. Following the completion of the transaction, the chief executive officer now owns 186,904 shares in the company, valued at approximately $685,937.68. This represents a 3.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amit Gupta also recently made the following trade(s):

• On Thursday, October 24th, Amit Gupta sold 22,607 shares of Cardlytics stock. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95.

Cardlytics Stock Down 8.4 %

Shares of NASDAQ CDLX traded down $0.32 during mid-day trading on Monday, reaching $3.49. 2,033,344 shares of the company's stock were exchanged, compared to its average volume of 1,212,448. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm has a market capitalization of $177.37 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. The business has a fifty day simple moving average of $3.93 and a 200 day simple moving average of $4.85.

Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business had revenue of $67.06 million during the quarter, compared to analysts' expectations of $57.77 million. During the same period in the prior year, the business earned ($0.26) EPS. Cardlytics's revenue for the quarter was down 15.1% compared to the same quarter last year. As a group, equities analysts expect that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC acquired a new position in Cardlytics in the 3rd quarter worth $82,000. Barclays PLC lifted its holdings in shares of Cardlytics by 223.9% in the third quarter. Barclays PLC now owns 58,026 shares of the company's stock valued at $186,000 after purchasing an additional 40,112 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cardlytics by 7.5% during the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock worth $3,371,000 after buying an additional 73,484 shares during the period. Quadrature Capital Ltd bought a new position in shares of Cardlytics during the third quarter worth about $63,000. Finally, RBF Capital LLC grew its holdings in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company's stock worth $1,562,000 after buying an additional 369,620 shares in the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CDLX has been the topic of a number of recent research reports. Craig Hallum raised shares of Cardlytics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 6th. Evercore ISI started coverage on Cardlytics in a research note on Friday, October 11th. They issued an "in-line" rating and a $4.00 price target for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Cardlytics currently has an average rating of "Hold" and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.